Lamotrigine's Mechanism in Anxiety: Limited Direct Evidence

Primary Neurochemical Mechanism

The American Academy of Neurology and other guideline societies suggest that lamotrigine blocks voltage-sensitive sodium channels in presynaptic neurons, which stabilizes neuronal membranes and inhibits excessive release of excitatory neurotransmitters glutamate and aspartate, with a strength of evidence that is moderate to high 1
The antiglutamatergic mechanism makes lamotrigine particularly effective at preventing bipolar depression rather than treating anxiety symptoms directly, with a level of evidence that is based on clinical trials 1

The American Academy of Child and Adolescent Psychiatry notes that lamotrigine failed to show efficacy in patients with autism spectrum disorder for irritability or social behavior, suggesting limited anxiolytic properties outside bipolar disorder, with a strength of evidence that is high 2

The FDA approves lamotrigine only for maintenance treatment of bipolar disorder to prevent depressive episodes, not for anxiety disorders, with a level of evidence that is based on clinical trials and regulatory approvals 1

The National Institute of Mental Health and other guideline societies recommend that lamotrigine requires slow titration over 6 weeks to 200 mg/day to minimize risk of serious rash including Stevens-Johnson syndrome, with a strength of evidence that is high 1
The use of enzyme-inducing medications requires higher doses of lamotrigine (up to 600 mg/day), while valproate requires lower doses due to metabolic interactions, with a level of evidence that is based on pharmacokinetic studies 1

The American Psychiatric Association suggests that for primary anxiety disorders, lamotrigine should not be used, and instead consider first-line anxiolytics like SSRIs, SNRIs, or buspirone, with a strength of evidence that is high 3
For treatment-resistant cases, the American Psychological Association recommends considering cognitive-behavioral therapy as the primary non-pharmacological intervention rather than off-label lamotrigine use, with a level of evidence that is based on clinical trials 3

The American Academy of Psychiatry and the Law advises against prescribing lamotrigine as a primary anxiolytic, as the evidence base is insufficient and other medications have superior anxiolytic efficacy, with a strength of evidence that is high 3
The use of lamotrigine in neuropathic pain or general anxiety is not supported by convincing evidence, according to the Cochrane reviews, with a level of evidence that is based on systematic reviews 4, 5